Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Receivables (2022 - 2025)

BioXcel Therapeutics has reported Receivables over the past 4 years, most recently at $233000.0 for Q4 2025.

  • Quarterly results put Receivables at $233000.0 for Q4 2025, up 77.86% from a year ago — trailing twelve months through Dec 2025 was $233000.0 (up 77.86% YoY), and the annual figure for FY2025 was $233000.0, up 77.86%.
  • Receivables for Q4 2025 was $233000.0 at BioXcel Therapeutics, up from $17000.0 in the prior quarter.
  • Over the last five years, Receivables for BTAI hit a ceiling of $812000.0 in Q2 2024 and a floor of $3000.0 in Q3 2024.
  • Median Receivables over the past 4 years was $248000.0 (2022), compared with a mean of $303818.2.
  • Peak annual rise in Receivables hit 88.4% in 2024, while the deepest fall reached 99.59% in 2024.
  • BioXcel Therapeutics' Receivables stood at $248000.0 in 2022, then crashed by 71.37% to $71000.0 in 2023, then skyrocketed by 84.51% to $131000.0 in 2024, then soared by 77.86% to $233000.0 in 2025.
  • The last three reported values for Receivables were $233000.0 (Q4 2025), $17000.0 (Q2 2025), and $131000.0 (Q4 2024) per Business Quant data.